Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Significant Growth in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 2,004 shares, an increase of 235.7% from the June 30th total of 597 shares. Based on an average daily volume of 10,079 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Santen Pharmaceutical currently has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Up 3.0%

Shares of OTCMKTS SNPHY opened at $12.00 on Tuesday. The business has a fifty day simple moving average of $12.48 and a 200 day simple moving average of $11.54. The firm has a market capitalization of $3.87 billion and a price-to-earnings ratio of 0.10. Santen Pharmaceutical has a one year low of $9.22 and a one year high of $13.93.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.